Under new legislation, the FDA and NIH will receive discretionary funding to combat antibiotic resistant bacteria and advance prevision medicine initiatives.
Data falsification at API facilities is getting harder to spot say regulators who have called for more systems training and international collaboration.
Protea Biosciences has teamed up with Agilent Technologies to offer drugmakers mass spectrometry alternatives to UV detection in QA/QC of recombinant proteins.
If even the apparently non-joke, potential US presidential candidate Donald Trump criticizes your behaviour, you must know what you are doing is unpopular.
Last week another Google spinoff, Verily, released a video introducing itself to the world and its goal of using technology to create “a true picture of human health.”
A new single-use bioproduction plant will bring in annual revenues of $40m, says Avid Bioservices which is already eyeing up additional capacity to cope with contract manufacturing demand.
Reliance on third-party software vendors differentiates INC Research from its technology-investing peers but will not be a disadvantage, according to a Jefferies analyst.
Early and efficient communication is the key to cutting approval times says the US FDA, which published a draft best practices guide for drug firms this week.
Growth-hungry CROs will buy trial sites according to David Blume from Edgemont Capital Partners, who told us Icon's acquisition of PMG Research is part of an emerging trend.
Aptuit plans to up tabletting and encapsulation capacity at sites in the UK and Italy less than a year after it increased API output at the same facilities.
AMRI has opened a drug discovery center, citing growing customer demand for biology, high-throughput screening, in vitro pharmacology, and medicinal chemistry at a single site.
Salary increases will only help CROs hold on to staff for so long according to the author of a wages study who says retention is ultimately about building loyalty.
Danaher has bought production line monitoring and coding tech firm Laetus to bolster its life science product ID offering ahead of a planned corporate split next year.
Korean regulators have approved a second Samsung Bioepis biosimilar, this time granting the JV rights to sell a version of J&J's Remicade (infliximab).
Increasing interest in human genome sequencing and editing is driving demand for oligonucleotides, says Integrated DNA Technologies (IDT) which is buying AITbiotech’s synthesis business in Singapore.
